Indication and Limitation of Intradiscal Condoliase Injection for Patients with Lumbar Disc Herniation: Literature Review and Meta-Analysis

Overview

Journal Spine Surg Relat Res

Date 2024 Aug 12

PMID 39131408

Authors

Hideaki Nakajima

Shuji Watanabe

Kazuya Honjoh

Arisa Kubota

Akihiko Matsumine

Affiliations

Soon will be listed here.

Abstract

Background: Intradiscal condoliase injection for lumbar disc herniation (LDH) was developed in Japan in 2018. The treatment is intermediate between conservative therapy and surgery, and its frequency is increasing. Condoliase is limited to a single application over a lifetime, rendering it important to understand the indications and predictors of its effectiveness. This review aimed to summarize published studies and provide appropriate indications and limitations for appropriate patient selection based on existing findings.

Methods: While adhering to PRISMA guidelines, we searched the PubMed, Web of Science, and EMBASE databases to identify articles reporting the clinical outcomes of intradiscal condoliase injection for LDH. Data extraction focused on the effective rate, prognostic factors, and posttreatment imaging changes and was used in the meta-analysis.

Results: Nineteen studies met the inclusion criteria. Our meta-analysis revealed 78% total response, 11% posttreatment surgery, and 42% posttreatment Pfirrmann-classification-grade progression rates. Posttreatment intervertebral disc degeneration was potentially associated with an improved response rate and disc regeneration one year posttreatment, especially in young patients. The Regimen for patients aged <20 and >70 years should be carefully selected, including those with a disease duration of >1 year, recurrent LDH, small-sized LDH, vertebral instability, and inadequate duration (<3 months) of conservative therapy.

Conclusions: Although long-term outcomes and imaging changes must be evaluated owing to the heterogeneity of previous studies, intradiscal condoliase injection is a minimally invasive and cost-effective treatment option for patients with LDH. Treatment indications should be determined after carefully evaluating evidence from previous conservative and surgical treatments.

References

Banno T, Hasegawa T, Yamato Y, Yoshida G, Arima H, Oe S . Disc degeneration could be recovered after chemonucleolysis with condoliase.-1 year clinical outcome of condoliase therapy. J Orthop Sci. 2021; 27(4):767-773. DOI: 10.1016/j.jos.2021.05.005. View

Agre K, WILSON R, Brim M, McDermott D . Chymodiactin postmarketing surveillance. Demographic and adverse experience data in 29,075 patients. Spine (Phila Pa 1976). 1984; 9(5):479-85. View

Banno T, Hasegawa T, Yamato Y, Yoshida G, Yasuda T, Arima H . Clinical outcome of condoliase injection treatment for lumbar disc herniation: Indications for condoliase therapy. J Orthop Sci. 2020; 26(1):79-85. DOI: 10.1016/j.jos.2020.02.002. View

Matsuyama Y, Seo T, Chiba K . Condoliase chemonucleolysis for lumbar disc herniation: A post-hoc follow-up study of patients in previous clinical trials. J Orthop Sci. 2022; 28(4):724-732. DOI: 10.1016/j.jos.2022.04.003. View

Cuellar J, Stauff M, Herzog R, Carrino J, Baker G, Carragee E . Does provocative discography cause clinically important injury to the lumbar intervertebral disc? A 10-year matched cohort study. Spine J. 2015; 16(3):273-80. DOI: 10.1016/j.spinee.2015.06.051. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Kim K, Kim Y, Lee C, Shin M . MRI classification of lumbar herniated intervertebral disc. Orthopedics. 1992; 15(4):493-7. DOI: 10.3928/0147-7447-19920401-18. View

Kanaan T, Abusaleh R, Abuasbeh J, Al Jammal M, Al-Haded S, Al-Rafaiah S . The Efficacy of Therapeutic Selective Nerve Block in Treating Lumbar Radiculopathy and Avoiding Surgery. J Pain Res. 2020; 13:2971-2978. PMC: 7680787. DOI: 10.2147/JPR.S276331. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

10.

Ohtonari T, Torii R, Noguchi S, Kitagawa T, Nishihara N . Short-term clinical and radiographic outcomes of chemonucleolysis with condoliase for painful lumbar disc herniation and analysis regarding intradiscal injection area. Neurosurg Rev. 2023; 46(1):59. DOI: 10.1007/s10143-023-01966-w. View

11.

Rahme R, Moussa R, Bou-Nassif R, Maarrawi J, Rizk T, Nohra G . What happens to Modic changes following lumbar discectomy? Analysis of a cohort of 41 patients with a 3- to 5-year follow-up period. J Neurosurg Spine. 2010; 13(5):562-7. DOI: 10.3171/2010.5.SPINE09818. View

12.

Ishibashi K, Fujita M, Takano Y, Iwai H, Inanami H, Koga H . Chemonucleolysis with Chondroitin Sulfate ABC Endolyase for Treating Lumbar Disc Herniation: Exploration of Prognostic Factors for Good or Poor Clinical Outcomes. Medicina (Kaunas). 2020; 56(11). PMC: 7699387. DOI: 10.3390/medicina56110627. View

13.

Lurie J, Tosteson T, Tosteson A, Zhao W, Morgan T, Abdu W . Surgical versus nonoperative treatment for lumbar disc herniation: eight-year results for the spine patient outcomes research trial. Spine (Phila Pa 1976). 2013; 39(1):3-16. PMC: 3921966. DOI: 10.1097/BRS.0000000000000088. View

14.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

15.

Nygaard O, Kloster R, Solberg T . Duration of leg pain as a predictor of outcome after surgery for lumbar disc herniation: a prospective cohort study with 1-year follow up. J Neurosurg. 2000; 92(2 Suppl):131-4. DOI: 10.3171/spi.2000.92.2.0131. View

16.

Ohtori S, Inoue G, Orita S, Eguchi Y, Ochiai N, Kishida S . No acceleration of intervertebral disc degeneration after a single injection of bupivacaine in young age group with follow-up of 5 years. Asian Spine J. 2013; 7(3):212-7. PMC: 3779773. DOI: 10.4184/asj.2013.7.3.212. View

17.

Banno T, Hasegawa T, Yamato Y, Yoshida G, Arima H, Oe S . Condoliase therapy for lumbar disc herniation -2 year clinical outcome. J Orthop Sci. 2022; 29(1):64-70. DOI: 10.1016/j.jos.2022.11.005. View

18.

Fjeld O, Grovle L, Helgeland J, Smastuen M, Solberg T, Zwart J . Complications, reoperations, readmissions, and length of hospital stay in 34 639 surgical cases of lumbar disc herniation. Bone Joint J. 2019; 101-B(4):470-477. DOI: 10.1302/0301-620X.101B4.BJJ-2018-1184.R1. View

19.

Oshita Y, Matsuyama D, Sakai D, Schol J, Shirasawa E, Emori H . Multicenter Retrospective Analysis of Intradiscal Condoliase Injection Therapy for Lumbar Disc Herniation. Medicina (Kaunas). 2022; 58(9). PMC: 9501482. DOI: 10.3390/medicina58091284. View

20.

Takaki S, Miyama H, Iwasaki M . Cost-effectiveness analysis of intradiscal condoliase injection vs. surgical or conservative treatment for lumbar disc herniation. J Med Econ. 2023; 26(1):233-242. DOI: 10.1080/13696998.2023.2173465. View